FDA Panel Unanimously Recommends Centocor’s Ustekinumab
This article was originally published in The Pink Sheet Daily
Executive Summary
But Dermatologic and Ophthalmic Drugs panel says the proposal for long-term safety follow-up is inadequate.
You may also be interested in...
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
Stelara Clears FDA; Different Mechanism of Action, But REMS Looks Similar To TNF Class
Centocor's newest anti-inflammatory biologic - ustekinumab - actually has a different mechanism than the TNF inhibitors, but FDA has the sponsor using a risk management program similar to existing TNF drugs.